ArticleVascular health and risk management2026
Multilayer Timing of Cardiac Circadian Regulation Informs Prevention and Treatment of Cardiovascular Disease.
Article in Vascular health and risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circadian control of immune homeostasis in cardiovascular health and disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular diseases remain the leading cause of death and economic burden worldwide. Increasing evidence indicates that sleep disturbance and circadian rhythm disruption are major risk drivers for hypertension, coronary artery disease, heart failure, and arrhythmia. Although the classical transcription-translation feedback loop (TTFL) model explains the basic mechanism of rhythm generation, increasing evidence suggests that the heart-an organ with high metabolic demand-maintains circadian stability through coordinated transcriptional, translational, and post-translational regulation. Methods: We developed an integrative, time-resolved, multilayer in silico framework to systematically analyze cardiac circadian regulation by combining mouse heart time-series RNA-seq (GSE54650), proteomics (PXD002870), phosphoproteomics (PXD036824), BMAL1 and Rev-erbα ChIP-seq, and enhancer RNA (eRNA) datasets. Rhythmicity was assessed using MetaCycle, with cross-layer comparisons evaluating concordance and divergence between transcriptomic and proteomic rhythms, and translation efficiency (TE) estimated from protein-to-mRNA ratios. Enhancer-gene coupling, transcription factor binding, and phosphorylation motif analyses were integrated to investigate multilayer regulatory coordination. Results: We identified 2552 rhythmic transcripts and 139 rhythmic proteins, with only 31 genes rhythmic at both layers, indicating substantial RNA-protein phase decoupling in the heart. Temporal stability of TE correlated positively with protein amplitude, suggesting that stable translation supports robust protein rhythmicity. Phosphoproteomic analyses revealed enrichment of SP motifs mediated by proline-directed kinases in rhythmic proteins. BMAL1 binding was associated with enhanced transcriptional amplitude, whereas REV-ERBα binding was associated with delayed target gene expression, forming complementary enhancer-level regulatory dynamics. Conclusion: This study supports a multilayered integrative model of cardiac circadian regulation in which rhythmic gene expression is jointly shaped by transcriptional activation, translational precision, and post-translational modification. By extending the classical "clock-transcription-protein" paradigm, our findings highlight enhancer-level control mediated by BMAL1 and Rev-erbα as an important mechanism contributing to the stabilization of cardiac circadian timing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.